- Home
- FMST vs CMMB Comparison
FMST vs CMMB Comparison
Compare FMST & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- CMMB
- Stock Information
- Founded
- FMST 2005
- CMMB 2004
- Country
- FMST Canada
- CMMB Israel
- Employees
- FMST N/A
- CMMB N/A
- Industry
- FMST Other Metals and Minerals
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- FMST Basic Materials
- CMMB Health Care
- Exchange
- FMST Nasdaq
- CMMB Nasdaq
- Market Cap
- FMST 39.6M
- CMMB 22.0M
- IPO Year
- FMST N/A
- CMMB N/A
- Fundamental
- Price
- FMST $2.42
- CMMB $1.13
- Analyst Decision
- FMST
- CMMB Strong Buy
- Analyst Count
- FMST 0
- CMMB 2
- Target Price
- FMST N/A
- CMMB $8.50
- AVG Volume (30 Days)
- FMST 376.8K
- CMMB 113.5K
- Earning Date
- FMST 01-01-0001
- CMMB 08-20-2025
- Dividend Yield
- FMST N/A
- CMMB N/A
- EPS Growth
- FMST N/A
- CMMB N/A
- EPS
- FMST N/A
- CMMB N/A
- Revenue
- FMST N/A
- CMMB N/A
- Revenue This Year
- FMST N/A
- CMMB N/A
- Revenue Next Year
- FMST N/A
- CMMB N/A
- P/E Ratio
- FMST N/A
- CMMB N/A
- Revenue Growth
- FMST N/A
- CMMB N/A
- 52 Week Low
- FMST $0.55
- CMMB $0.87
- 52 Week High
- FMST $5.74
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- FMST 39.09
- CMMB 35.18
- Support Level
- FMST $2.32
- CMMB $1.12
- Resistance Level
- FMST $2.89
- CMMB $1.23
- Average True Range (ATR)
- FMST 0.27
- CMMB 0.05
- MACD
- FMST -0.11
- CMMB 0.00
- Stochastic Oscillator
- FMST 8.70
- CMMB 8.82
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.